TGTX Trading Analysis - 10/30/2026 04:03 PM — TRU-SENTIMENT

News Headlines & Context

The following items are provided from general knowledge for context only and are separate from the data-driven analysis below:

• TGTX (TG Therapeutics) recently announced continued uptake of its MS drug Briumvi, with management guiding for stronger H2 2026 prescriptions.
• Company presented positive long-term efficacy data at a major neurology conference in Q3 2026, a potential catalyst for sentiment.
• No confirmed near-term earnings date in this context, but fiscal year end is 2025-12-01 per fundamentals, with potential updates expected.
• Biotech sector has seen rotational interest amid broader risk-on moves, which may support small/mid-cap names like TGTX.
• Context: Strong options flow and technical strength below may reflect anticipation of continued commercial execution rather than reported news.

Fundamental Analysis

Based strictly on the embedded FUNDAMENTALS data for TGTX:

• Trailing P/E is 19.10 with trailing EPS of 3.04; valuation appears moderate versus typical biotech peers with profitability.
• Market cap is 9,323,432,790.00 with shares outstanding of 153,069,000.00.
• Dividend yield is 0.00; no dividend rate or ex-dividend date provided.
• Beta is 1.30, indicating above-market volatility relative to broad indices.
• 52-week high is 59.30 and 52-week low is 26.76; current price near 57.99 is close to the annual high.
• Institutional ownership is 52.51%, reflecting moderate institutional participation.
• Average volume is 1,477,000.00; historical volatility is 33.63%.
• PEG ratio, forward P/E, forward EPS, profit margins, ROE, debt/equity, and free cash flow are null — not available in data.
• Analyst consensus and target mean price are null; no Wall Street target context provided.
• Fundamentals show profitability (positive EPS) and moderate multiple, aligning with technical strength and bullish options flow, but lack of margin/debt data limits deeper quality assessment.

Current Market Position

From the minute bars and daily history, TGTX opened 2026-10-29 at 57.81 and closed at 57.99. On 2026-10-30, the last bars show price at 15:35 of 60.91, with a high of 61.10 at 15:30. Recent daily close on 2026-10-29 was 57.99, and the 30-day range high is 58.96 / low 51.34.

Intraday momentum on 2026-10-30 was upward: from 09:30 base near 57.62 to 60.91 close, with volume spikes at 15:30 (38,285) and 15:35 (31,178) confirming late-session strength.

Technical Analysis

• SMA alignment: 5-day (56.15) > 50-day (55.12) > 20-day (54.53); price 57.99 above all, bullish stack.
• RSI at 61.09 shows moderate bullish momentum, not overbought (<70).
• MACD line 0.49 above signal 0.39, histogram +0.10, confirms bullish crossover state.
• Bollinger mid 54.53, upper 57.45, lower 51.60; price 57.99 is above upper band — expansion signal.
• 30-day high 58.96 / low 51.34; price at 57.99 is near top 95% of range.

True Sentiment Analysis (Delta 40-60 Options)

Based on True Sentiment Options data for 2026-10-30:

Call Volume: 1,214,300.00 (95.70%) Put Volume: 54,940.00 (4.30%) Total: 1,269,240.00

• Sentiment tag: Bullish per methodology (Delta 40-60 only).
• Call contracts 1,780 vs put 71; call trades 13 vs put 5 — strong directional conviction.
• Pure directional positioning suggests near-term upside expectations, matching technical breakout.
• No divergence: both sentiment and price action agree bullish; only 5.80% of total options met filter (18 of 312).

Key Price Levels (Observational Only)